COMMUNIQUÉS West-GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024

08/11/2024 - 18:00

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: [...]

EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024

08/11/2024 - 18:00

Nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

08/11/2024 - 18:00

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]

Pearson Medical Technologies Introduces m:Print Bar Code Labeling Software v4 for Pharmacy Drug Supply Chain Security Act (DSCSA) Compliance

08/11/2024 - 18:23

ALEXANDRIA, La., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Pearson Medical Technologies announces the international release of m:Print® Bar Code Labeling Software Version 4 , a powerful new upgrade of its industry-leading [...]

Ardelyx Responds to District Court Decision Granting Motion to Dismiss

08/11/2024 - 18:31

Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients’ health at risk WALTHAM, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company [...]

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

08/11/2024 - 19:30

Objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months in first line (1L) HPV+ R/M HNSCC patients treated with CUE-101 and KEYTRUDA ® ( [...]

Extendicare Announces New $275 Million Senior Secured Credit Facility

08/11/2024 - 20:18

MARKHAM, Ontario, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced that it has entered into a new senior secured credit facility for $275.0 million (the “ [...]

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

08/11/2024 - 15:00

Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology Enrolling patients in the investigator-sponsored trial with [...]

AVITA Medical to Host Investor Webinar Briefing

08/11/2024 - 15:00

VALENCIA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]

Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease

08/11/2024 - 15:00

First randomized placebo-controlled trial in NTM abscessus Symptom-based endpoints showed favorable improvement in frequency and severity of the most common symptoms Microbiologic endpoints showed higher conversion to [...]

Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)

08/11/2024 - 15:00

Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end. Encouraging clinical responses observed in monotherapy (KVA12123 [...]

Director/PDMR Shareholding

08/11/2024 - 15:00

DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support [...]

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

08/11/2024 - 15:07

Bagsværd, Denmark, 8 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]

Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024

08/11/2024 - 15:30

Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & Development Presentations and seminars highlighted [...]

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

08/11/2024 - 15:55

The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to CervoMed recognizes the [...]

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

08/11/2024 - 16:00

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2 SK ) to the tumor microenvironment (TME), where [...]

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

08/11/2024 - 16:05

New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy. Predictive biomarkers correlated [...]

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences

08/11/2024 - 17:03

8 November 2024 New Release BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of T he NGAL Test to Clinicians at Major Healthcare Conferences COPENHAGEN, DENMARK and BOSTON [...]

GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Gene Vector Therapy, at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

08/11/2024 - 12:00

GEN2 was studied in patients with hepatocellular carcinoma or advanced solid tumors metastatic to the liver and was well-tolerated at all dose levels administered 21% of patients remained on study for >6 months, with [...]